An Observational Study of Patients With Chronic Lymphocytic Leukemia Treated With Fixed Duration Therapy in a 1L Setting in Canada.

INTRODUCTION

Targeted fixed duration (FD) therapies have emerged as new treatment options that have been shown to be highly effective for patients with chronic lymphocytic leukemia (CLL). To date, there is limited Canadian data on the uptake and outcomes of CLL treatment following the approval of FD therapy.

PATIENTS AND

METHODS

This study was conducted to evaluate the clinical and demographic characteristics, treatment outcomes, and healthcare resource utilization (HCRU) of CLL patients treated with FD treatments in the 1L setting between 01 January 2010 and 31 December 2023 in Alberta, Canada.

RESULTS

In total, 589 patients received therapy for CLL during this time period, and venetoclax plus obinutuzumab (VO) represented the most common therapy from 2021 to 2023. Additionally, patients receiving VO showed the highest survival rates at 12 months (95% confidence interval [CI]) at 97.6% (94.5, 100.0), followed by fludarabine, cyclophosphamide, and rituximab (FCR) at 96.6% (94.0, 99.3).

CONCLUSION

These results highlight the shift in the treatment landscape for CLL with the potential for improved patient outcomes.